Current through Register Vol. 40, No. 6, March 31, 2022
Role of Federal
The use of buprenorphine for
the treatment of opioid addiction is governed by the federal Drug Addiction
Treatment Act of 2000, commonly referred to as "DATA 2000" (
, Title XXXV, Sections 3501 and 3502). This
legislation allows physicians to treat opioid addiction with FDA-approved
controlled drugs in office-based settings. Specifically, DATA 2000 allows
physicians to use buprenorphine and other controlled substances in the federal
Controlled Substances Act (
, et. seq.) (CSA)
Schedules III, IV, and V, which have been approved by the FDA for the treatment
of opioid dependence, to treat patients in office-based settings, provided
certain conditions are met.
DATA 2000 lifted the requirement that patients who need opioid agonist
treatment can receive such treatment only in specially licensed opioid
treatment programs (OTPs), often referred to as "methadone clinics."
(c) For the implementation of DATA 2000, the
Secretary of the Department of Health and Human Services (HHS) delegated
authority in this area to the Center for Substance Abuse Treatment (CSAT) of
the Substance Abuse and Mental Health Services Administration (SAMHSA).
Role of State
(a) The use of opioid agonist
medications to treat opioid-addicted patients in the offices of individual
physicians significantly increases the role of state medical boards in
overseeing such treatment. For this reason, the Federation of State Medical
Boards (FSMB) entered into an agreement with SAMHSA to develop model guidelines
for use by state medical boards in regulating office-based treatment of
(b) The agreement
between FSMB and SAMHSA resulted in a Model Policy adopted by FSMB in 2002. The
Model Policy was updated in April 2013. The Model Policy encourages state
medical boards to adopt consistent standards, to promote the public health by
making appropriate treatment available to opioid-addicted patients, and to
educate the regulatory and physician communities about the potential of new
treatment modalities for opioid addiction.
1These rules are directly based on
the Federation of State Medical Boards Model Policy on DATA 2000 and Treatment
of Opioid Addiction in the Medical Office, April 2013, and the authorities
referenced and cited in that policy. The complete Federation of State Medical
Boards Model Policy with references and citations may be accessed at
Ala. Admin. Code r.
Administrative Monthly Volume XXXIII, Issue No. 06, March 31,
2015, eff. 4/23/2015.
Author: Alabama Board of Medical
Code of Ala.